Skip to content

The Effect of Home Blood Pressure Measurement on the Management of Hypertension

Evaluation of Home Blood Pressure Measurement for the Management of Hypertension in Treated Hypertensive Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03868384
Enrollment
701
Registered
2019-03-11
Start date
2018-08-01
Completion date
2026-12-31
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ambulatory Blood Pressure, Blood Pressure, Home Blood Pressure Measurement, Hypertension

Brief summary

Home blood pressure measurement has been reported to be associated with better clinic blood pressure and daytime blood pressure control. However, no study has evaluated the association between home blood pressure measurement and control of 24-hour ambulatory blood pressure in real world practice. The purpose of the present study is to investigate the effect of home blood pressure measurement on the control of ambulatory blood pressure in the real world. The detailed purposes of the present study are (1) to investigate the effects of home blood pressure measurement on the appropriate control of 24-hour ambulatory blood pressure in hypertensive patients treated with antihypertensive drug, (2) to evaluate the effect of home blood pressure measurement on the occurrence of cardiovascular events and target organ damage, (3) to investigate the status and appropriateness of home blood pressure measurement in the real world, and (4) to investigate factors of home blood pressure measurement methods affecting the treatment of hypertension.

Interventions

None listed

Sponsors

DongGuk University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with hypertension and taking antihypertensive drugs more than 1 year

Exclusion criteria

* Secondary hypertension * Hypertensive emergency and urgency * Severe heart failure (NYHA III and IV) * Angina with 6 months * Myocardial infarction within 6 months * Peripheral artery disease within 6 months * Significant arrhythmia (i.e. ventricular tachycardia and fibrillation, atrial fibrillation, atrial flutter) * Pregnancy * Night labor, shift worker * Those who are currently participating in other clinical studies * Those who have taken other clinical trial drugs within the past month * According to the opinion of the researcher, those who have or may have a disease that may interfere with the completion of the study * History of drug or alcohol dependence within 6 months

Design outcomes

Primary

MeasureTime frameDescription
Difference of 24-hour blood pressure control rateat baseline and 3 years of follow updifference of 24-hour blood pressure control rate between patients who measure and do not measure home blood pressure

Secondary

MeasureTime frameDescription
Difference of office blood pressure control rateat baseline and 3 years of follow upDifference of office blood pressure control rate between patients who measure and do not measure home blood pressure
Difference of systolic and diastolic blood pressure (office, 24-hour, daytime, nighttime)at baseline and 3 years of follow upDifference of systolic and diastolic blood pressure (office, 24-hour, daytime, nighttime) between patients who measure and do not measure home blood pressure
Rate of home blood pressure measurementat baseline and 3 years of follow upRate of home blood pressure measurement in study population
Difference of daytime blood pressure control rateat baseline and 3 years of follow upDifference of daytime blood pressure control rate between patients who measure and do not measure home blood pressure
cardiovascular disease prevalence and target organ damageat baseline and 3 years of follow upDifference of cardiovascular disease prevalence and target organ damage between patient who do or do not measure home blood pressure * Composites of cardiovascular disease: number of participants with non-fatal myocardial infarction, angina pectoris, revascularization of arteries, stroke, transient ischemic attack, atrial fibrillation, heart failure hospitalization, progression to end-stage renal failure or elevation of creatinine more than 2-fold, other undefined cardiovascular events at the discretion of the investigator * Target organ damage: left ventricular hypertrophy by electrocardiography, brachial-ankle pulse wave velocity, microalbuminuria
Changes of home blood pressure measurement ratefrom baseline to 3 years of follow upChanges of home blood pressure measurement rate in study population after 3 year of follow up from baseline
Cardiovascular disease events and target organ damageduring 3 years of follow up from baseline measurementDifference of occurrence of cardiovascular disease events and target organ damage between patient who measure and do not measure home blood pressure * Composites of cardiovascular disease events: number of participants with first occurrence of non-fatal myocardial infarction, angina pectoris, revascularization of arteries, stroke, transient ischemic attack, atrial fibrillation, heart failure hospitalization, progression to end-stage renal failure or elevation of creatinine more than 2-fold, other undefined cardiovascular events at the discretion of the investigator * Target organ damage: left ventricular hypertrophy by electrocardiography, brachial-ankle pulse wave velocity, microalbuminuria from enrollment
Reflection of home blood pressureat baseline and 3 years of follow upRate of reflecting home blood pressure in the treatment of hypertension at office

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026